Caplacizumab (Cablivi) in India – Where to Buy & Availability Guide

Cablivi or caplacizumab-yhdp is a targeted antibody fragment used to treat acquired thrombotic thrombocytopenic purpura (aTTP) in adults. It works by binding to the A1-domain of the von Willebrand factor (vWF), preventing its interaction with platelets which reduces abnormal platelet adhesion and consumption. It is used alongside plasma exchange and immunosuppressive therapy.

The primary side effect of treatment with caplacizumab is hemorrhage as it increases the risk of potentially fatal bleeding, especially in those with underlying coagulopathies such as hemophilia or other coagulation factor deficiencies. Hence, concomitant use of antiplatelet agents or anticoagulants should be avoided. Monitoring and management of bleeding, if it occurs, is required

 

No information regarding the presence of caplacizumab in human milk, effects on children being breastfed or on milk production.  However, the condition of the mother, developmental and health benefits of breastfeeding as well as  potential adverse effects on the breastfed child should be considered. Safety and effectiveness of caplacizumab use in pediatric patients has not been established. Due to insufficiency of subjects over 65 years of age,  safety and effectiveness in geriare=tric patients cannot be established. Since, no formal studies have been conducted in patients with severe acute or chronic hepatic impairment under caplacizumab treatment, considering the potential risk of bleeding, patients require close monitoring. 


PRICING AND AVAILABILITY

Caplacizumab is not registered for commercial sale in India and is therefore unavailable through standard pharmacies or local distributors. As this is a prescription-only therapy, pricing details for those who want to buy caplacizumab in India are provided upon request, following the submission of valid medical documents and a doctor’s prescription. For the latest pricing information and procurement assistance, patients or caregivers are encouraged to contact our team directly.

The price of caplacizumab in India may vary depending on several factors, including supplier source, market conditions, regulatory requirements, and international availability. Additional elements such as shipping costs, documentation fees, origin country, and currency exchange rates may also influence the final price.

Fluctuations in GST or local taxes, as well as adjustments in manufacturer pricing policies, can further affect total cost.

We facilitate patient access to caplacizumab in India under the Named Patient Supply (NPS) program, ensuring full legal and regulatory compliance. Our dedicated support team oversees the process from document verification to final delivery, ensuring safety and transparency at each stage.

ACCESS PATHWAY

Since caplacizumab is not commercially licensed in India, it can only be accessed through the Named Patient Import Program (NPIP). Through this route, we assist patients in obtaining unregistered medicines like caplacizumab under the NPS framework, in accordance with applicable import regulations. Caplacizumab is available as 11 mg, white lyophilized powder in a single-dose vial. 

IMPORT PROCESS

  1. Submission of Request: Patients or caregivers initiate the process by submitting a formal request, along with treatment details and a valid prescription.

  2. Form 12A Application: An application must be submitted in Form 12A, accompanied by a prescription issued by a Registered Medical Practitioner (RMP).

  3. Document Verification: All submitted medical and identification documents are reviewed to confirm eligibility for import under the personal medical use category.

  4. Regulatory Authorization: Upon approval from the Drugs Controller General (India), the import procedure is initiated as per the approved prescription.

  5. Global Sourcing: Our procurement team collaborates with authorized international suppliers to source the medicine at the most competitive rate, ensuring product authenticity and compliance.

  6. Delivery and Fulfilment: Following regulatory approval, logistics and customs procedures are coordinated to ensure secure, compliant, and timely delivery to the patient’s address in India.

REQUIRED DOCUMENTATION

To facilitate import of caplacizumab into India, patients are required to provide:

  • A valid doctor’s prescription specifying the medicine name, dosage, treatment duration, and diagnosis.

  • Recent medical history and supporting laboratory reports (preferably within the past three months).

  • Government-issued identification and proof of residence of the patient.

  • Import permit (if applicable).

Orders are finalized only upon receipt of all required documents and verification of medical eligibility. Once the import permit is approved, the licensed supplier arranges shipment of caplacizumab from approved international sources such as the United States, Canada, Europe, or Australia.

We ensure that every import of caplacizumab in India is conducted safely, ethically, and in full regulatory compliance. Our organization provides nationwide delivery through verified suppliers, guaranteeing product authenticity and complete transparency in pricing and process. All prescriptions are reviewed and dispensed by registered pharmacists prior to delivery.

Any patients searching for detailed information or pricing contact 247qualitymeds.com.

Comments

Post a Comment

Popular posts from this blog

Myth vs Fact: Blincyto Edition

Image
Blinatumomab (Blincyto) in India Blincyto is a Bispecific T-cell engager (BiTE) immunotherapy used for the treatment of certain B-cell precursor acute lymphoblastic leukemia (ALL). Since it works differently from chemotherapy, it has led to curiosity and confusion. These confusions lead to misconceptions to patients, so here’s the article to burst the myth and present the facts. MYTH: Blincyto ( Blinatumomab ) works for all types of leukemia FACT: Blincyto is indicated in adults and children above one month old with: CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%.   Relapsed or refractory CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL).  CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (ALL) in the consolidation phase of multiphase chemotherapy.  MYTH: Side-effects of Blincyto are sam...
Read more

Not All Immune Protection Starts with a Vaccine: What Makes Cytogam Different?

Image
Cytogam CMV 50 mg for Injection available in India  Most people are familiar with the two primary approaches used to protect the body against viral infections: vaccines and antiviral medications. Antiviral drugs work by targeting specific stages of a virus's life cycle. They interfere with the virus's ability to replicate, spread, or produce the proteins it needs to survive within the body. Vaccines, in contrast, help train the immune system to recognize and respond to a particular pathogen before an infection occurs, enabling the body to build its own defense mechanisms. However, there is a third approach that is often overlooked. It is neither a vaccine nor an antiviral drug, yet it plays an important role in protecting certain high-risk patients. This approach is known as hyperimmune globulin therapy. Understanding the Basics Hyperimmune globulin therapy provides immediate immune protection by supplying antibodies that have already been formed. Unlike vaccines, which require...
Read more

Pemigatinib in India: Availability, Pricing & Access Pathways Explained

Image
Buy pemigatinib (Pemazyre) tablets in India For patients looking for pemigatinib in India , finding the medicine can involve a different process from purchasing a conventional prescription medicine from a local pharmacy. Pemigatinib, sold under the brand name Pemazyre, is an oral targeted therapy that inhibits fibroblast growth factor receptors (FGFR1, FGFR2 and FGFR3). It is used for specific cancers in which these pathways are altered, including previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or rearrangement and relapsed or refractory myeloid/lymphoid neoplasms with an FGFR1 rearrangement. In India, access can involve individual-patient importation rather than routine retail pharmacy supply. Understanding the prescription, documentation, sourcing, storage, delivery and monitoring requirements can help patients and caregivers navigate the process more confidently. The Current Situation of Pemazyre in India Why This Therapy Is N...
Read more